Clinicopathologic significance of genetic alterations in hepatocellular carcinoma

被引:40
作者
Pang, A
Ng, IO
Fan, ST
Kwong, YL
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med Professorial Block, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Med Professorial Block, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, Dept Med Professorial Block, Dept Surg, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1016/S0165-4608(03)00103-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatocarcinogenesis may involve multiple mutations with distinctive pathogenetic and clinicopathologic significance. To test this hypothesis, 68 cases of hepatocellular carcinoma (HCC) were studied prospectively for genetic-clinicopathologic correlation. Ten pathologic characteristics were evaluated. TP53 (alias p53) gene mutation was studied by a polymerase chain reaction (PCR)-single-strand conformation polymorphism-sequencing; CDKN2B (alias p15) and CDKN2A (alias p16) gene methylation by methylation-specific PCR; and genetic imbalances by comparative genomic hybridization (CGH). TP53 gene mutations occurred in 25% of cases, more than half being codon 249 G to T transversion. Methylation of CDKN2A was frequent (61.7%); of CDKN2B, rare (5.9%). The CGH analysis showed a median of nine aberrations per case, with amplifications more frequent than deletions. Isochromosomes might be involved in about 25% of cases. Amplifications of 1q and 8q were most frequent. Clinicopathologic correlations showed that CDKN2A methylation was significantly associated with tumors arising in cirrhotic livers; amplifications of 17q was significant in multiple parameters of tumor invasiveness (size, venous invasion, poor cellular differentiation, microsatellite formation); other amplifications (1q, 6p, 10p, and 20p) were also significant in tumor invasion; and deletions (at 1p, 11q, 4q, and 14q) were significant in tumor growth. Consistent patterns of genetic alterations were defined in HCC, which might represent distinctive pathways in hepatocarcinogenesis. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:8 / 15
页数:8
相关论文
共 41 条
[1]  
AbouElella A, 1996, MODERN PATHOL, V9, P95
[2]   Tying it all together: Epigenetics, genetics, cell cycle, and cancer [J].
Baylin, SB .
SCIENCE, 1997, 277 (5334) :1948-1949
[3]  
BEASLEY RP, 1981, LANCET, V2, P1129
[4]   Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population [J].
Biden, K ;
Young, J ;
Buttenshaw, R ;
Searle, J ;
Cooksley, G ;
Xu, DB ;
Leggett, B .
HEPATOLOGY, 1997, 25 (03) :593-597
[5]  
BOSCH FX, 1991, ADV AP BIOT, V13, P35
[6]   LOW-FREQUENCY OF P53 MUTATIONS OBSERVED IN A DIVERSE COLLECTION OF PRIMARY HEPATOCELLULAR CARCINOMAS [J].
BUETOW, KH ;
SHEFFIELD, VC ;
ZHU, MH ;
ZHOU, TL ;
SHEN, FM ;
HINO, O ;
SMITH, M ;
MCMAHON, BJ ;
LANIER, AP ;
LONDON, WT ;
REDEKER, AG ;
GOVINDARAJAN, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (20) :9622-9626
[7]   Human DNA (cytosine-5) methyltransferase PCNA complex as a target for p21(WAF1) [J].
Chuang, LSH ;
Ian, HI ;
Koh, TW ;
Ng, HH ;
Xu, GL ;
Li, BFL .
SCIENCE, 1997, 277 (5334) :1996-2000
[8]   Hepatitis C virus and hepatocellular carcinoma [J].
Colombo, M .
SEMINARS IN LIVER DISEASE, 1999, 19 (03) :263-269
[9]  
EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO
[10]  
2-E